Targeted therapy

Articles

• dasatinib
  2 September 2008

  WP
  Definition: Dasatinib is a dual inhibitor of the src and abl tyrosine kinases. It was approved by the Federal Drug Administration for the treatment of imatinib mesylate-resistant chronic myeloid leukemia.
  Dasatinib inhibits juxtamembrane domain mutant KIT-D816V autophosphorylation and KIT-dependent activation of down stream signaling important for cell growth and survival of neoplastic cells.
  Additionally, dasatinib induces apoptosis in mast cell and leukemia cell lines expressing (...)

• durvalumab
  9 June 2016

  WP
  Durvalumab is one of PD-L1 inhibitors . It ismonoclonal antibody being investigated for the treatment of cancer. It targets programmed death ligand-1 (PD-L1), developed by MedImmune.
  Clinical trials
  non-small cell lung cancer (NSCLC) - trial combining durvalumab and gefitinib in NSCLC
  advanced metastatic urothelial bladder
  See also
  PD-L1 inhibitors
  immune (...)

• infliximab
  11 June 2007

  Remicade Wikipedia
  Definition: Infliximab (Remicade) is an antibody that blocks the effects of tumor necrosis factor alpha (TNF alpha or TNFA). Infliximab is administered by intervenous infusion.
  There are two other injectable drugs that block TNF alpha—adalimumab(Humira) and etanercept (Enbrel). TNF is a substance made by cells of the body which has an important role in promoting inflammation.
  Specifically, infliximab is used for treating the inflammation of Crohn’s disease, (...)

• crizotinib
  10 June 2010

  Pfizer drug crizotinibPF-02341066 or 1066, PF-02341066, Xalkori Wikipedia
  Molecular target: ALK
  Definition: Crizotinib is an ALK inhibitor , ROS1 inhibitor and MET inhibitor .
  Crizotinib is undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, advanced non-small cell lung carcinoma (NSCLC ).
  Crizotinib is an oral ALK (anaplastic lymphoma kinase) inhibitor under study in patients with advanced NSCLC carrying the echinoderm (...)